Philochem AG has disclosed conjugates comprising fibroblast activation protein α (FAP) ligands covalently linked to radiolabeled payloads through a linker. They are reported to be useful for the diagnosis of atherosclerosis, cancer, fibrosis, inflammation and keloids.